The orphan receptor, GPR88, is emerging as a key player in the pathophysiology of several neuropsychiatric diseases, including psychotic disorders. Knockout (KO) mice lacking GPR88 throughout the brain exhibit many abnormalities relevant to schizophrenia including locomotor hyperactivity, behavioural hypersensitivity to dopaminergic psychostimulants and deficient sensorimotor gating. Here, we used conditional knockout (cKO) mice lacking GPR88 selectively in striatal medium spiny neurons expressing A 2A receptor to determine neuronal circuits underlying these phenotypes. We first studied locomotor responses of A 2A R-Gpr88 KO mice and their control littermates to psychotomimetic, amphetamine, and to selective D1 and D2 receptor agonists, SKF-81297 and quinpirole, respectively. To assess sensorimotor gating performance, mice were submitted to acoustic and visual prepulse inhibition (PPI) paradigms. Total knockout GPR88 mice were also studied for comparison. Like total GPR88 KO mice, A 2A R-Gpr88 KO mice displayed a heightened sensitivity to locomotor stimulant effects of amphetamine and SKF-81297. They also exhibited enhanced locomotor activity to quinpirole, which tended to suppress locomotion in control mice. By contrast, they had normal acoustic and visual PPI, unlike total GPR88 KO mice that show impairments across different sensory modalities. Finally, none of the genetic manipulations altered central auditory temporal processing assessed by gap-PPI. Together, these findings support the role of GPR88 in the pathophysiology of schizophrenia and show that GPR88 in A 2A receptor-expressing neurons modulates psychomotor behaviour but not sensorimotor gating.
Introduction
GPR88 is an orphan G protein-coupled receptor (GPCR) that is highly enriched in medium spiny neurons of the neostriatum (caudate putamen and nucleus accumbens) and the olfactory tubercle (Logue et al., 2009; Massart et al., 2009; Quintana et al., 2012) . The distinctive pattern of GPR88 expression has generated considerable excitement regarding the physiological role of this orphan receptor and its implication in brain diseases associated with striatal dysfunction. Human genetic studies revealed a positive association between GPR88 and schizophrenia as well as bipolar disorder (Ogden et al., 2004; Del Zompo et al., 2014) . Deleterious mutation in GPR88 was also linked to a familial developmental disorder characterized by a childhood chorea (hyperkinetic movement disorder), learning disabilities and speech retardation (Alkufri et al., 2016) . Accordingly, studies conducted with knockout (KO) mice showed that GPR88 gene deletion leads to a wide range of behavioural abnormalities, including locomotor hyperactivity, stereotypic behaviour, motor coordination deficits, altered emotional processing and impaired associative and procedural learning (Logue et al., 2009; Quintana et al., 2012; Meirsman et al., 2016a,b) . Interestingly, local re-expression of GPR88 in the dorsal striatum (caudate putamen) counteracted the observed locomotor hyperactivity and learning deficits demonstrating causal link between GPR88 loss in the dorsal striatum and the behavioural phenotypes of KO mice (Quintana et al., 2012) . GPR88 KO mice were also reported to display an enhanced sensitivity to psychomotor effects of dopaminergic agonists (e.g. apomorphine and amphetamine) and deficient sensorimotor gating mechanisms (prepulse inhibition of acoustic startle reflex, PPI), behavioural abnormalities of relevance to schizophrenia and related psychotic disorders. Accordingly, both PPI deficits and apomorphine-induced stereotypies could be reverted by typical (haloperidol) and atypical (risperidone) neuroleptic treatments suggesting that altered GPR88 signalling may contribute to some aspects of schizophrenia syndrome (Logue et al., 2009) . By contrast, Ingallinesi et al. (2015) showed that local silencing of GPR88 in the ventral striatum (nucleus accumbens) produces no behavioural alterations in normal rats, but attenuates the schizophrenia-related phenotypes (amphetamine-induced locomotor hyperactivity and social novelty discrimination deficit) elicited by neonatal exposure to phencyclidine. Together, these findings highlight the complex role of GPR88 in the control of striatal function and suggest that dysfunction of GPR88 signalling may contribute to a range of neuropsychiatric disorders that involve abnormal motor, cognitive and emotional behaviour.
Despite major advance, the neuronal circuit underlying GPR88 function in the brain remains poorly understood. GPR88 expression in the striatum is confined to medium spiny projection neurons (MSNs) that form the vast majority of striatal neurons (Logue et al., 2009; Massart et al., 2009; Quintana et al., 2012) . MSNs are commonly segregated into two subpopulations based on receptor expression and projection targets. MSNs of the direct pathway express dopamine D1 receptors (D1R, D1R-MSNs) and project to the substantia nigra pars reticulata and the internal segment of the globus pallidus (entopeduncular nucleus in rodents), whereas MSNs of the indirect pathway contain dopamine D2 (D2R, D2R-MSNs) and adenosine A 2A receptors (A 2A R) and innervate the substantia nigra pars reticulata via the external segment of the globus pallidus (GPe) and subthalamic nucleus (Albin et al., 1989) . These two populations of MSNs are known to differentially participate in striatal functions and behavioural output as they are coupled with output pathways with opposing properties (Durieux et al., 2009 (Durieux et al., , 2012 Bateup et al., 2010; Kravitz et al., 2010; Lobo et al., 2010) . Recently, we generated conditional knockout (cKO) mice lacking GPR88 receptor selectively in A 2A R-expressing neurons (A 2A R-Gpr88 KO, Meirsman et al., 2016b) . We showed that A 2A R-Gpr88 KO mice recapitulate many of the phenotypes of total Gpr88 KO mice, including the locomotor hyperactivity and the abnormal emotional reactivity and sociability, thus revealing the role of GPR88 in A 2A R-expressing neurons in the modulation of these complex behavioural traits.
In the present follow-up study, we investigated the contribution of GPR88 in A 2A R-expressing neurons to the modulation of sensorimotor gating and susceptibility to psychomotor effect to dopaminergic drugs, behavioural traits relevant to psychotic disorders. We first compared the susceptibility of A 2A R-Gpr88 KO mice and their control littermates to psychomotor effects of amphetamine. The selective D1R agonist, SKF-81287, and D2R agonist, quinpirole, were also used to evaluate the locomotor responses of mice to direct dopamine receptor stimulation. To gain a better insight on the role of GPR88 in the modulation of sensorimotor gating, A 2A R-Gpr88 KO and control mice were assessed in acoustic and visual PPI paradigms. Finally, the impact of GPR88 ablations on auditory temporal processing was also evaluated using gap detection based on recent evidence implicating GPR88 in hearing loss (Marley et al., 2013) and developmental delay of speech (Alkufri et al., 2016) . Total GPR88 KO mice were included in all studies for comparison.
Materials and methods

Animals
Mice of both genders aged between 10 and 15 weeks were used in this study. Mice were bred in house and group housed three to five animals per cage. They were maintained on a 12-h light/dark cycle at controlled temperature (22 AE 1°C). All experiments were conducted during the light phase. Food and water were available ad libitum throughout all experiments. All experiments were approved by the local ethic comity (CREMEAS, 2003-10-08-[1] -58). For total (Gpr88 À/À ; background: 13.96% C57B1/6; 60.94% C57B1/6J; 0.05% FVB/N; 25% 129/SvPas; 0.05% SJL/J) and A 2A R-Gpr88 KO mice (Gpr88 A2AR-Cre ; background: 1.08% C57B1/6; 16.78% C57B1/6J; 0.01% FVB/N; 53.17% 129/SvPas; 0.01% SJL/J; 29.54% C57B1/6N) construction as well as conditional deletion was described previously (Meirsman et al., 2016a,b) . Also, we previously showed that introduction of loxP sites in the mouse Gpr88 gene had no impact on GPR88 receptor agonist-induced activation in homozygous floxed mice (Gpr88 flx/flx ) compared to wild-type animals (Gpr88 +/+ ) (Meirsman et al., 2016b 
Behavioural procedures
Independent cohorts of na€ ıve Gpr88 A2AR-Cre and control mice (Gpr88 Flx/Flx ) were used for amphetamine (n = 12 for each genotype), dopamine receptor direct agonists (n = 32 for Gpr88
Flx/Flx and 34 for Gpr88 ) and PPI studies (n = 8 for Gpr88 flx/flx and 10 for Gpr88 A2A-Cre ). For comparison, three independent cohorts of naive Gpr88
À/À and wild-type mice (Gpr88 +/+ ) were included for amphetamine (n = 18 per genotype), dopamine receptor agonists (n = 24 per genotype) and PPI studies (n = 19 for Gpr88 +/+ and 17 for Gpr88
À/À
). All mice were tested for PPI in the following order: acoustic PPI, visual PPI and gap detection paradigms. Resting periods of at least 48 h were used between two successive PPI testings.
Locomotor response to dopaminergic drugs
Testing was carried in transparent single cages (21 9 11 9 17 cm) under dim light (10 Lux). Locomotor activity was monitored via an automated videotracking system (View Point, Lyon, France). For amphetamine-induced locomotion, control and mutant mice were first placed in the unfamiliar cages for one hour to habituate to the novel environment. At the end of this first testing period, mice were allocated to 2.5 mg/kg of amphetamine (n = 7 Gpr88
Flx/Flx , 6 Gpr88 A2AR-Cre ; n = 9 Gpr88
Gpr88
Flx/Flx , 6 Gpr88 A2AR-Cre ; n = 9 Gpr88 +/+ , 9 Gpr88 À/À ) and their locomotor activity was immediately assessed for one hour. A similar protocol was used for dopamine receptor agonist studies. Upon habituation session, Gpr88 Flx/Flx and Gpr88 A2AR-Cre mice were allocated to 2.5 mg/kg SKF-81297 (n = 8 and 10, respectively); 0.1 mg/kg quinpirole (n = 12 per genotype) or saline treatment (n = 12 per genotype). Similarly, Gpr88
+/+ and Gpr88 À/À mice were allocated to SKF-81297 (N = 6 and 9, respectively), quinpirole (N = 6 per genotype) and saline treatment (N = 12 and 9, respectively). D-Amphetamine sulphate (Sigma, USA), SKF-81297 and quinpirole hydrochloride (Tocris, France) were dissolved in isotonic saline solution (NaCl 0.9%) and injected subcutaneously in a volume of 10 mL/kg.
Acoustic startle reflex and PPI
Testing was carried in eight startle reflex devices (SRLAB, San Diego, CA, USA). Each device consisted of a ventilated soundattenuated cubicle equipped with an animal enclosure (a Plexiglas cylinder with 5.1 cm outside diameter mounted on a Plexiglas platform). A high-frequency loudspeaker, placed 28 cm above the animal enclosure produces both a continuous background noise (65 dB) and the various acoustic stimuli. A piezoelectric accelerometer attached to the Plexiglas platform detects and transduces the movements of the animals within the cylinder. The visual stimuli (flashes of lights) were provided by a visual kit consisting of 10 white LEDs (5 mm in diameter/5600 m.c.d.; Marl International Optosource, Cumbria, Los Angeles, CA) and mounted on the top of the cylinder. Before each PPI session, piezo accelerometer sensitivity as well as acoustic and visual stimuli levels were calibrated. Startle amplitude was obtained from the recording of 65 readings of 1 ms beginning at the stimulus onset.
Acoustic PPI procedure
The session started by a 5-min acclimation period followed by five consecutive startling pulses (white-noise 110-dB/40 ms) that were excluded from the analysis. Ten different trial types were then presented in a random order: startling pulse alone; eight different prepulse trials in which either 10 ms long 70, 80, 85 or 90 dB stimuli were presented alone or preceded the startling pulse by 50 ms, and finally one trial in which only the background noise (BN) was presented to measure the baseline movement in the Plexiglas cylinder.
Intertrial intervals lasted 20 s in average (15-25 s).
Visual PPI procedure
The session started by a 5-min acclimation period followed by five consecutive startling pulses (white-noise 110-dB/40 ms) that were excluded from the statistical analysis. Eleven different trial types were then presented: startling pulse alone, visual prepulse (1000 Lux/ 20 ms) presented alone or at various intervals (2, 10, 20, 50, 100, 200, 500 and 2000 ms between prepulse offset and pulse onset) before the startling pulse, and finally a trial in which only the BN was presented.
All trials were applied 10 times and presented in random order with an intertrial interval of 20 s in average (15-25 s).
Gap-PPI procedure
The session started by a 5-min acclimation period followed by five consecutive startling pulses (white-noise 120-dB/40 ms) that were excluded from the statistical analysis. Ten different trial types were then presented: startling pulse alone, a brief silent gap of various durations (5, 10, 15, 20, 25, 30, 35 and 40 ms) inserted immediately before the startling pulse, and a trial in which only the BN was presented. All trials were applied 10 times and presented in random order with an intertrial interval of 20 s in average (15-25 s).
Statistics
Drug-induced locomotion data were analysed using two-way ANOVA with genotypes as the between-subject factor and treatment as the within-subject factor. Post hoc comparisons analyses were carried out using Bonferroni's multiple comparisons test whenever the ANOVA showed significant effects. PPI performance was expressed as percentage decrease in the amplitude of basal startle reflex caused by presentation of the prepulse (% PPI) according to the following formula: % PPI = 100 * [(mean startle responses to the pulse alone) À (mean startle responses to the prepulse + pulse)]/mean startle responses to the pulse alone. Global acoustic and visual PPI performances (mean % PPI scores) were pooled across all prepulse intensities and intervals, respectively. Global gap-PPI performances were pooled across all gap durations. PPI and gap-PPI data were analysed by RM two-way ANOVA with genotypes as the betweensubject factor and the stimuli parameters (prepulse intensities, prepulse-pulse intervals and gap durations) as the repeated measures.
Post hoc comparisons analysis were carried out using Bonferroni's multiple comparisons test whenever the two-way ANOVAs indicated statistically significant main or interaction effects. All statistics were performed using GRAPHPAD PRISM 6 (GraphPad Software Inc, USA), and the accepted level of significance was P < 0.05.
Results
Locomotor activity response to dopamine agonists
As depicted in Fig. 1A , Gpr88 A2AR-Cre mice were more sensitive to the locomotor stimulant effect of an acute (2.5 mg/kg) amphetamine treatment. Two-way ANOVA revealed a significant effect of genotype (F 1,20 = 6.702, P = 0.0175) and pharmacological treatment (F 1,20 = 12.86, P = 0.0018). Post hoc comparisons show a significant difference between amphetamine-treated mice (P < 0.01, Bonferroni's multiple comparisons test) but not saline-injected mice. Likewise (Fig. 1B) , acute treatment with D1R agonist (SKF-81297, 2.5 mg/kg) significantly increased locomotion in both control and mutant mice when compared to saline treatment (P < 0.001; Bonferroni's multiple comparison test), but had an exacerbated effect in Gpr88 A2AR-Cre when compared to control mice (P < 0.001; Bonferroni's multiple comparisons test). Two-way ANOVA indicates a genotype (F 1,60 = 21.24, P < 0.0001) and treatment effect (F 2,60 = 67.35, P < 0.0001). Analysis also revealed a significant genotype 9 treatment interaction (F 2,60 = 4.76, P = 0.0121). In agreement, the D2R agonist (quinpirole, 0.1 mg/kg) decreased locomotion in control animals compared to saline-treated mice (not significant) but had the opposite effect on Gpr88 A2AR-Cre mice. Post hoc comparison indicates a significant difference between genotypes for D2R-agonist treated animals (P < 0.01; Bonferroni's multiple comparisons test) but not saline-treated mice.
Similar to conditional KO mice, Gpr88 À/À KO mice displayed an increased amphetamine-induced locomotion when compared to wildtype animals (Fig. 1C) . Two-way ANOVA showed a significant genotype (F 1,32 = 30.61, P < 0.0001) and treatment (F 1,32 = 183.2, P < 0.0001) effect. Post hoc comparisons show that while locomotion after saline injection did not differ between genotypes, when injected with 2.5 mg/kg of amphetamine total KO mice travelled a significantly increased distance (P < 0.0001, Bonferroni's multiple comparisons test). Similarly, acute injection of D1R agonist significantly increased locomotion in both wild-type and total KO mice when compared to saline treatment (P < 0.001; Bonferroni's multiple comparisons test) with enhanced locomotion in mutants compared to control animals (P < 0.05, Bonferroni's multiple comparisons test) (Fig. 1D) . Analysis of variance indicate a significant genotype (F 1,42 = 33.69; P < 0.0001) and treatment (F 2,42 = 46.59, P < 0.0001) effect. As for conditional KO mice, ANOVA also revealed a significant genotype x treatment interaction (F 2,42 = 8.54, P = 0.0008) probably associated with an opposite locomotor response of wild types and KO animals to D2R agonist treatment. Also, post hoc comparisons indicate a significant difference between genotypes after D2R injection (P < 0.0001, Bonferroni's multiple comparisons test).
Auditory sensorimotor gating in Gpr88 A2AR-Cre and Gpr88
À/À KO mice Figure 2A , illustrates acoustic PPI performances of Gpr88 A2AR-Cre and Gpr88 Flx/Flx control mice as function of the prepulse intensity. PPI level increased similarly in both genotypes when the prepulse intensity was raised from 70 to 90 dB. Two-way ANOVA showed a significant effect of prepulse intensity (F 3,48 = 135.6, P < 0.0001), but failed to reveal a significant effect of genotype (F 1,16 = 1.12, P = 0.3057) or a significant genotype 9 prepulse intensity interaction (F 3,48 = 0.878, P = 0.4589). Mean PPI scores pooled across all prepulse intensities were also comparable between genotypes (t 16 = 1.026, P = 0.32; Student's t-test, Fig. 2B ). From Table 1 , it can be seen that Gpr88 A2AR-Cre mice had normal baseline startle response compared to their littermates (t 16 = 0.14, P = 0.89; Student's t-test, Table 1 ). Presentation of acoustic prepulse alone tended to evoke a slight reaction at the highest intensities (≥ 85 dB), but no difference was detected between genotypes (Table 1) .
Figures 2C illustrates acoustic PPI performances of Gpr88 À/À KO mice and their wild-type littermates. PPI level increased progressively in both genotypes with increasing prepulse intensity (F 3,102 = 258.7, P < 0.0001), but KO mice had overall a poor performance. Accordingly, two-way ANOVA showed a significant effect of genotype (F 1,34 = 11.96, P = 0.0015) and post hoc comparisons indicated that total KO mice had significantly lower scores than wild types at 80 and 85 dB prepulse intensities (P < 0.05 and P < 0.01 respectively, Bonferroni's multiple comparisons test, Fig. 2C ).
Inspection of global PPI scores confirmed the poor performance of KO mice (t 34 = 3.44, P = 0.0016; Student's t-test, Fig. 2D ). No differences in baseline startle response or reactivity to acoustic prepulses were detected between genotypes (t 34 = 0.42, P = 0.68; Student's t-test Table 1 ). Locomotor effects of dopamine agonists in mice lacking Gpr88. After the habituation phase (data not shown), Gpr88 A2AR-Cre mice (A) show exacerbated locomotor hyperactivity after 2.5 mg/kg amphetamine injection compared to Gpr88 flx/flx control mice (n = 5-7 per treatment and genotype). (B) D1R agonist injection (SKF-81297 2.5 mg/kg, n = 8-12 per treatment and genotype) increased locomotion in mutant and control animals with Gpr88 A2AR-Cre mice presenting increased total distance travelled when compared to control mice. Conditional KO mice also present enhanced total distance travelled after D2R stimulation (quinpirole 0.1 mg/kg, n = 12 per treatment and genotype) when compared to their control littermates. Similarly, total GPR88 KO mice (C) present a potentiated increase in locomotion after amphetamine (n = 9 per treatment and genotype À ) and D1R agonist (n = 6-12 per treatment and genotype) treatment (D), compared to Gpr88 +/+ mice. Like conditional KO, Gpr88 À/À mice show enhanced locomotion compared to wild-type mice after D2R agonist injection (n = 6-12 per treatment and genotype). Lines represent mean and SEM, and all animals are represented as data points. Text stars (*): one star P < 0.05; two stars P < 0.01; three stars P < 0.001 (vs. control animals, Bonferroni's multiple comparisons test). Dollar sign ($) three stars P < 0.001 (vs. saline treatments, Bonferroni's multiple comparisons test).
Visual sensorimotor gating in Gpr88
A2AR-Cre and Gpr88 À/À KO mice Figure 3A illustrates visual PPI of Gpr88 A2AR-Cre and Gpr88
Flx/Flx mice as function of the prepulse-pulse interval. The time function of visual PPI was similar between genotypes, a bell-shaped curve with a peak of inhibition at 20-ms lead time interval. Two-way ANOVA showed a significant effect of interval (F 7,112 = 9.47, P < 0.0001), but failed to reveal a significant effect of genotype (F 1,16 = 0.69, P = 0.4198) or a significant genotype x interval interaction (F 7,112 = 0.37, P = 0.9178). Global PPI scores pooled across all prepulse-pulse intervals were also comparable between genotypes (t 16 = 0.84, P = 0.41 Figure 3B) . No difference in baseline ) present increased PPI levels with the increasing prepulse intensities. When compared to control littermates, Gpr88 A2A-Cre mice present normal acoustic PPI (A and B) Conversely, Gpr88 À/À show impaired general PPI (D) with significant decrease for prepulses of 80 and 85 dB (C). Data are represented as mean AE SEM, and all animal are represented as data points. Solid stars: two stars P < 0.01 (Student's t-test). Text stars (*): one star P < 0.05; two stars P < 0.01 (Bonferroni's multiple comparisons test). startle response was detected between Gpr88 A2AR-Cre and control mice ( Table 2) . Presentation of the visual prepulse alone did not produce any overt reactions in mice, unlike acoustic prepulses (Table 2) . Figure 3C illustrates the temporal profile of visual PPI for Gpr88 À/À and wild-type mice. Both genotypes showed a bell-shaped curve with a maximal level of inhibition at 20-ms prepulse-pulse interval, but KO mice had again a poor PPI performance (Fig. 3C ).
There was a significant effect of genotype (F 1,34 = 4.13, P = 0.0499) and post hoc comparisons indicated that KO mice had a lower PPI scores than wild types at 20-ms lead time interval (P < 0.01, Bonferroni's multiple comparisons test, Fig. 3C ). Significant difference between genotypes was also found for global PPI scores (t 34 = 2.048, P = 0.048; Student's t-test, Fig. 3D ). Baseline startle responses were comparable between KO and wild-type mice (t 34 = 0.14, P = 0.89; Student's t-test, Table 2 ).
Gap detection in Gpr88 A2AR-Cre and Gpr88 À/À mice Figure 4A shows that Gpr88 A2AR-Cre mice had a normal gap detection compared to Gpr88
Flx/Flx control animals. Two-way ANOVA showed a significant effect of gap duration (F 7,112 = 129.5, P < 0.0001), but failed to reveal a significant effect of genotype (F 1,16 = 1.36, P = 0.2613). Global scores pooled across all gap durations (Fig. 4B) and baseline startle responses (Table 3) were also comparable between genotypes (t 16 = 0.26, P = 0.80; Student's t-test).
Similarly, no difference in gap detection was observed between Gpr88 À/À KO mice and their wild-type counterparts (F 1,34 = 0.69, P = 0.4105, Fig. 4C ). Global scores (Fig. 4D ) and baseline startle response (Table 3) were also comparable between genotypes (t 34 = 0.66, P = 0.52; Student's t-test).
Discussion
GPR88 is selectively and highly expressed in medium spiny neurons of the striatum and has been implicated in the pathophysiology of psychotic disorders. Previous studies showed that GPR88 gene deletion throughout the brain increases spontaneous locomotor activity and exacerbates locomotor responses of mice to amphetamine (Quintana et al., 2012; Meirsman et al., 2016a,b) . Our findings extend these observations and demonstrate that striatal MSNs expressing A 2A R play a central role in relaying the inhibitory influence of GPR88 on these behavioural traits. The hypersensitivity of Gpr88 A2AR-Cre mice to psychomotor effect of amphetamine may likely involve post-synaptic D2R mechanisms as striatal A 2A R are expressed in D2R-MSNs that give rise to the indirect pathway. To address this possibility, we tested the locomotor responses of Gpr88 A2AR-Cre mice to selective D1R and D2R stimulation using SKF81297 and quinpirole, respectively. As demonstrated by numerous studies, D2R plays a dual role in the modulation of locomotor activity. In mice, DR2 agonists reduce locomotor activity over a wide dose range (Ralph & Caine, 2005; Li et al., 2010) , an effect attributed to presynaptic D2 autoreceptors that inhibit dopamine release (Usiello et al., 2000; Wang et al., 2000) . However, the psychomotor stimulant actions of D2 agonists can be unmasked by pharmacological and genetic manipulations that lead to a hypersensitivity of post-synaptic D2R (Gomeza et al., 1999; Gainetdinov et al., 2003; Thompson et al., 2010; Espinoza et al., 2015) . Accordingly, quinpirole reduced spontaneous locomotor activity in control mice while it produced a robust locomotor hyperactivity in Gpr88 A2AR-Cre mice. Similar opposite locomotor effects of quinpirole were also seen in total GPR88 KO and their wild-type counterparts, as previously reported by Quintana et al. (2012) . Gpr88 A2AR-Cre mice were also more sensitive to psychomotor effects of the D1R agonist, SKF-81297, indicating that deletion of GPR88 in A 2A R-expressing MSNs alters striatal physiology beyond D2R-MSNs. Collectively, these observations suggest that enhanced functioning of post-synaptic D1R and D2R at striatal MSNs may underlie the locomotor phenotype of Gpr88 A2AR-Cre mice. However, other mechanisms cannot be excluded as GPR88 ablation might also produce transcriptional and anatomical modifications as previously found in total KO mice (Quintana et al., 2012; Meirsman et al., 2016a) . It should also be stressed that striatal cholinergic interneurons have been reported to express A 2A R transcripts. Although it is still unclear whether GPR88 is also present in the former neurons (Massart et al., 2009; Van Waes et al., 2011; Quintana et al., 2012) , the possibility that cholinergic mechanism may contribute to the locomotor phenotypes of Gpr88 A2AR-Cre mice cannot be completely ruled out. GPR88 was also implicated in the modulation of sensorimotor gating, a pre-attentive sensory filtering mechanism that is central to perceptual and mental integration (Logue et al., 2009) . In the present study, we confirm the acoustic PPI impairment reported in total GPR88 KO mice and further demonstrate that sensorimotor gating deficit generalizes to visual stimuli. The presentation of the flash light at varying intervals before the pulse produced the typical temporal profile of visual PPI in wild-type and KO mice: a bell-shaped curve with a sharp peak of inhibition occurring at short (20 ms) lead time interval (Aubert et al., 2006; Ces et al., 2012) . Interestingly, KO mice displayed a poor performance at lead time intervals starting from 20 to 100 ms, a temporal window corresponding to the effective startle inhibition. PPI is considered to reflect a transient activation of a 'protective gate' triggered by detection (or perception) of the prepulse. The activation of this gating mechanism allows the processing of the prepulse to occur without disruption by the succeeding pulse . Several lines of evidence indicate that PPI deficits of GPR88 KO mice reflect a disruption of the gating mechanisms rather than reduced detectability/temporal processing of the prepulses. Indeed, KO mice had normal motor reactions to acoustic prepulses (Table 1) and also normal gap detection, which rule out deleterious effects of the mutation on auditory function. The pattern of deficits obtained with visual PPI also argues against an impairment of the visual prepulse detection. As demonstrated by previous studies, decrement in visual sensitivity or visual prepulse strength causes a delay in the onset of PPI: a shift of the bell-shaped curve to the right (Aubert et al., 2006; Ces et al., 2012) . However, no shift in the onset of PPI was detected in KO mice. The present findings clearly show that GPR88 loss causes a genuine disruption of the gating processes that is generalized across sensory modalities as reported in schizophrenia patients (Braff et al., 2001 ).
An important result was that GPR88 deletion in A 2A R/D2R-expressing MSNs had no impact on sensorimotor gating. The absence of effect on acoustic PPI is somewhat not surprising knowing that D1R rather than D2R plays a prominent role in the modulation of acoustic PPI in mice. Indeed, several research groups, including our, showed that direct stimulation of D1R but not D2R produces disruption of acoustic PPI in mice, a pharmacological profile opposite to that obtained in rats (Ralph-Williams et al., 2002; Ralph & Caine, 2005; Geyer, 2006; Ces et al., 2012) . Our data therefore extend these mouse studies by showing that genetic deletion of GPR88 activity in striatal D2R-MSNs is ineffective on acoustic PPI. To unravel a possible impact of the mutation on sensorimotor gating, we used visual PPI, which is highly sensitive to D2R perturbations (Ces et al., 2012) . However, no deficit in visual PPI was detected in Gpr88 A2AR-Cre mice as compared to the control mice. It is worth noting that Gpr88 A2AR-Cre mice display also normal performance in series of associative (contextual and cued fear conditioning, Meirsman et al., 2016b) and non-associative learning tasks (habituation after repeated exposure to spatial context, data not shown), unlike total GPR88 KO mice that exhibit cognitive impairments (Logue et al., 2009; Quintana et al., 2012; Meirsman et al., 2016a,b) . The lack of phenotype suggests that GPR88 modulation of mnemonic functions and pre-attentive filtering processes may not operate at the level of A 2A R/D2R-expressing MSNs. Future studies using conditional knockout mice should clarify whether such cognitive functions are subserved by GPR88 in D1R expressing MSNs.
Finally, the impact of GPR88 ablations on gap detection (a brief gap inserted in the background noise that acts as a prepulse) was also assessed based on recent studies pointing to the role of this orphan receptor in hearing loss (Marley et al., 2013) and in developmental speech delay (Alkufri et al., 2016) . Gap detection is widely used as a measure of central auditory temporal processing, which is critical for speech perception and phonological processing (Phillips, 1999) . For instance, impairments of gap detection have been directly linked to speech perception deficits in children with language learning disorders and in elderly adults (Phillips, 1999; Walton, 2010) . Gap detection deficits have been also reported in patients with autism spectrum disorder that is linked to dysfunction of the cortico-basal ganglia-cortical loop (Bhatara et al., 2013) . As expected, presentation of the brief gap produced a robust inhibition of the startle response to the pulse as seen with the acoustic and the visual prepulses. However, no notable alteration was detected in either total GPR88 KO or conditional Gpr88 A2AR-Cre mice. The differential effect of GPR88 ablation on PPI and gap detection is particularly interesting as it demonstrates the specific contribution of GPR88 to brain processes filtering incoming sensory stimuli.
In conclusion, our findings confirm the modulatory role of GPR88 on sensorimotor gating. More importantly, they shed a new light on the function of striatal GPR88. They show that GPR88 in A 2A R/D2R-expressing MSNs play a prominent role in the modulation of locomotor responses to dopaminergic agonists and suggest altered postsynaptic D1R and D2R sensitivity. By contrast, it does not contribute to sensorimotor gating. These findings complement our previous work showing that GPR88 in striatal A 2A R/D2R-expressing MSNs acts as an important modulator of risk taking behaviours and social behaviour (Meirsman et al., 2016b) . Recent human genetic studies have implicated GPR88 in both schizophrenia and bipolar disorder (Ogden et al., 2004; Del Zompo et al., 2014) . Our work corroborates these studies and further suggests that alterations of GPR88 signalling in A 2A R-expressing neurons may contribute to some aspect of psychomotor agitation associated with these psychiatric diseases.
